Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Procollagen galactosyltransferase 1 (COLGALT1), also known as GLT25D1, is a key endoplasmic reticulum-resident enzyme belonging to the glycosyltransferase 25 family. It catalyzes the transfer of beta-galactose to specific hydroxylysine residues of procollagen, a critical early step in collagen post-translational modification and O-glycosylation. This modification is essential for proper collagen folding, triple-helix formation, secretion, and subsequent extracellular matrix assembly. Mutations in the COLGALT1 gene lead to underglycosylated collagen and are associated with brain small vessel disease 3 (BSVD3), characterized by vascular fragility, porencephaly, and intracranial hemorrhage. Additionally, altered expression of COLGALT1 has been implicated in fibrosis and the progression of certain cancers, such as kidney renal clear cell carcinoma, where it correlates with poor prognosis and an immunosuppressive tumor microenvironment. Currently, there are no approved drugs or active clinical candidates targeting this enzyme, but it represents an emerging biomarker and potential therapeutic target for modulating collagen-related pathologies.
No approved drugs or established small-molecule inhibitors target this enzyme. In a therapeutic context, potential mechanisms would involve inhibition of its galactosyltransferase activity to modulate collagen deposition in fibrosis or cancer, or gene therapy/enzyme replacement to restore activity in genetic deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Procollagen galactosyltransferase 1 (COLGALT1).